MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
The Lancet Microbe
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

103 results · 1 filter active ·
Results by year
20202025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
103 works in the cohort · of 4,299,418page 2 of 3

Labels cover 1 of 103 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 103 of 103 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study
Melinda Hamer, James McCarty, Benjamin C. Pierson, Jason A. Regules, Jason Mendy, Aaron D Sanborn +13 more
2025· article· en· The Lancet Microbe· Medicine
machine prediction:candidate · noneconsensus · none
14
citations
affaboutunlabeled
Global spread of clade Ib mpox: a growing concern
Ashutosh Pareek, Runjhun Singhal, Aaushi Pareek, Anil A. Chuturgoon, Vasso Apostolopoulos, Vijay Kumar Chattu
2025· article· en· The Lancet Microbe· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
12
citations
affunlabeled
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
Maheshi Ramasamy, Elizabeth J. Kelly, Seth Seegobin, Paul I. Dargan, Ruth Payne, Vincenzo Libri +46 more
2023· article· en· The Lancet Microbe· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affaboutunlabeled
Reproducibility in science: important or incremental?
Robyn S. Lee, William P. Hanage
2020· article· en· The Lancet Microbe· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · metaresearchconsensus · metaresearch
8
citations
affunlabeled
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Sue Ann Costa Clemens, Brett Jepson, Qasim Bhorat, Abdullahi Ahmad, Tauseefullah Akhund, Parvinder K. Aley +17 more
2024· article· en· The Lancet Microbe· Medicine
machine prediction:candidate · noneconsensus · none
7
citations

How this was built: Screen · Findings · About